Seguir
Magnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
Dirección de correo verificada de ki.se
Título
Citado por
Citado por
Año
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
M Ingelman-Sundberg, SC Sim, A Gomez, C Rodriguez-Antona
Pharmacology & therapeutics 116 (3), 496-526, 2007
13552007
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
The pharmacogenomics journal 5 (1), 6-13, 2005
12702005
Dietary long-chain n− 3 fatty acids for the prevention of cancer: a review of potential mechanisms
SC Larsson, M Kumlin, M Ingelman-Sundberg, A Wolk
The American journal of clinical nutrition 79 (6), 935-945, 2004
11772004
Metabolic gene polymorphism frequencies in control populations
S Garte, L Gaspari, AK Alexandrie, C Ambrosone, H Autrup, JL Autrup, ...
Cancer Epidemiology Biomarkers & Prevention 10 (12), 1239-1248, 2001
11062001
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim, C Risinger, ML Dahl, E Aklillu, M Christensen, L Bertilsson, ...
Clinical Pharmacology & Therapeutics 79 (1), 103-113, 2006
8882006
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
I Johansson, E Lundqvist, L Bertilsson, ML Dahl, F Sjöqvist, ...
Proceedings of the National Academy of Sciences 90 (24), 11825-11829, 1993
8231993
Pharmacogenomics and individualized drug therapy
M Eichelbaum, M Ingelman-Sundberg, WE Evans
Annu. Rev. Med. 57, 119-137, 2006
8012006
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
Trends in pharmacological sciences 25 (4), 193-200, 2004
7932004
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
M Ingelman-Sundberg, M Oscarson, RA McLellan
Trends in pharmacological sciences 20 (8), 342-349, 1999
7911999
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
MD Weltman, GC Farrell, P Hall, M Ingelman‐Sundberg, C Liddle
Hepatology 27 (1), 128-133, 1998
7671998
Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona, M Ingelman-Sundberg
Oncogene 25 (11), 1679-1691, 2006
6272006
Perinatal morbidity and mortality in early‐onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE)
C Lees, N Marlow, B Arabin, CM Bilardo, C Brezinka, JB Derks, J Duvekot, ...
Ultrasound in obstetrics & gynecology 42 (4), 400-408, 2013
623*2013
Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1)
G Ekström, M Ingelman-Sundberg
Biochemical pharmacology 38 (8), 1313-1319, 1989
6201989
Nomenclature for human CYP2D6 alleles.
AK Daly, J Brockmöller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ...
Pharmacogenetics 6 (3), 193-201, 1996
5891996
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
I Johansson, M Oscarson, QY Yue, L Bertilsson, F Sjöqvist, ...
Molecular pharmacology 46 (3), 452-459, 1994
5741994
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, ...
Journal of pharmacology and experimental therapeutics 278 (1), 441-446, 1996
5081996
Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease
CC Bell, DFG Hendriks, SML Moro, E Ellis, J Walsh, A Renblom, ...
Scientific reports 6 (1), 1-13, 2016
5012016
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
M Ingelman-Sundberg
Naunyn-Schmiedeberg's archives of pharmacology 369 (1), 89-104, 2004
4472004
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
ML Dahl, I Johansson, L Bertilsson, M Ingelman-Sundberg, F Sjöqvist
Journal of Pharmacology and Experimental Therapeutics 274 (1), 516-520, 1995
4311995
Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects
Y Zhou, M Ingelman‐Sundberg, VM Lauschke
Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017
4092017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20